However, the best available clinical information, derived from the phase 3 Cantos trial, which tested canakinumab to treat heart failure in a cohort of over 10,000 patients, showed that targeting IL-1β is associated with a reduction of death from all cancers (83), making it an excellent target for TAM depletion in combination with ICB. This evidence concerns the gene IL1B and cancer.